G7 Acetabular System With Vivacit-E or Longevity Liner PMCF Study
NCT04754087
Recruiting
The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Acetabular Shells when used with the Vivacit-E and Longevity HXLPE liners and instrumentation in primary and revision total hip arthroplasty.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Colorado Joint Replacement, Denver, Colorado +10 locations
Conditions: Total Hip Arthroplasty, Degenerative Joint Disease of Hip, Avascular Necrosis of Hip, Rheumatoid Arthritis of Hip, Osteoarthritis, Hip, Osteoarthritis of Hip, Fractures, Hip, Fracture of Hip
Register for Updates
Feasibility Study of Tissue and Blood Collection in Oncogene-addicted and Neoadjuvantly Treated Non Small Cell Lung Cancer
NCT07008742
Recruiting
This study aims to determine if it is feasible to collect samples of blood and viable lung cancer tissue in patients with either: * Stage IV mutation-driven NSCLC * Stage II-III NSCLC undergoing neoadjuvant immunotherapy prior to surgery Viable tissue has been defined by the collaborating pathology department as the presence of viable tumour cells, in accordance with recommendations from the International Association or the Study of Lung Cancer. In patients with stage IV NSCLC, obtaining adeq... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: The Royal Marsden NHS Foundation Trust, London, Not set
Conditions: Oncogene-addicted Non Small Cell Lung Cancer, Early-stage Operable Non Small Cell Lung Cancer, Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer, Stage 2/3 Operable Non Small Cell Lung Cancer
Register for Updates
Losartan and Emotional Processing in Young People
NCT06636812
Recruiting
This study explores the effects of single-dose losartan (50mg) versus placebo on emotional processing in young healthy volunteers.
Gender:
ALL
Ages:
Between 16 years and 20 years
Trial Updated:
06/12/2025
Locations: Warneford Hospital, University of Oxford, Oxford, Oxfordshire
Conditions: Emotional Processing
Register for Updates
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
NCT05131022
Recruiting
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: City of Hope, Duarte, California +60 locations
Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Waldenstrom Macroglobulinemia (WM), Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)
Register for Updates
Establishing Social Connections in Urban Areas: Evaluating a Community-based Programme
NCT06805136
Recruiting
The aim of this study is to evaluate the feasibility and acceptability of a new community-based programme designed to tackle loneliness for young and working-age adults. The programme focuses on encouraging social interactions and connections through offering community initiatives and activities, online spaces for interaction, and free or low-cost social events for young adults. Further aims of this study are to determine the cost-effectiveness of the programme.
Gender:
ALL
Ages:
Between 20 years and 40 years
Trial Updated:
06/12/2025
Locations: In the community in London, England, London, Not set +1 locations
Conditions: Loneliness
Register for Updates
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
NCT06165341
Recruiting
The liver produces a protein called alpha-1 antitrypsin (AAT). AAT is normally released into the bloodstream. In some people, the liver makes an abnormal version of the AAT protein, called Z-AAT. Making an abnormal version of the AAT protein can result in liver disease as Z-AAT builds up in liver cells, which leads to liver problems such as liver scarring (fibrosis), continuing liver damage (cirrhosis), and eventually endstage liver disease. Fazirsiran is a medicine that reduces the creation of... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/12/2025
Locations: St Joseph's Hospital and Medical Center, Phoenix, Arizona +35 locations
Conditions: Alpha1-Antitrypsin Deficiency
Register for Updates
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
NCT04557462
Recruiting
The purpose of this study is to evaluate the long-term safety and tolerability, of open label iptacopan in primary IgA nephropathy participants who have completed either the CLNP023X2203 or CLNP023A2301 clinical trials. The open-label design of the current study is appropriate to provide study participants the opportunity to receive treatment with iptacopan until marketing authorizations are received and the drug product becomes commercially available while enabling collection of long-term safet... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/12/2025
Locations: AZ Kidney Dise and Hypertension Ctr, Glendale, Arizona +145 locations
Conditions: Primary IgA Nephropathy
Register for Updates
A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™
NCT06320535
Recruiting
This is a phase I clinical study that aims to assess the safety and immunogenicity of a novel, escalating dose regimen of R21/Matrix-M™ in healthy, malaria-naïve adults.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
06/12/2025
Locations: Centre for Clinical Vaccinology and Tropical Meducine, Churchill Hospital, University of Oxford, Oxford, Oxfordshire +1 locations
Conditions: Malaria,Falciparum
Register for Updates
Exploratory Safety and Efficacy of EMP-01 in Social Anxiety Disorder
NCT06693609
Recruiting
This Phase 2 study (protocol number EMP-01-201) will determine the safety and tolerability of a short-term treatment with an oral dosage form of EMP-01 in adult participants with social anxiety disorder (SAD) and will assess exploratory efficacy of repeated doses of EMP-01 versus placebo.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/11/2025
Locations: MAC Clinical Research - South Staffordshire, Bridgetown, Cannock, Staffordshire +6 locations
Conditions: Social Anxiety Disorder
Register for Updates
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
NCT05587712
Recruiting
The primary objectives of the study are to evaluate the safety and tolerability, and pharmacokinetics (PK) of sotatercept over 24 weeks of treatment in children ≥1 to \<18 years of age with PAH World Health Organization (WHO) Group 1 on standard of care (SoC). There is no formal hypothesis.
Gender:
ALL
Ages:
Between 1 year and 17 years
Trial Updated:
06/11/2025
Locations: The Regents of the University of California - Los Angeles (UCLA Pediatrics) ( Site 1606), Los Angeles, California +34 locations
Conditions: Pulmonary Arterial Hypertension
Register for Updates
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
NCT05714085
Recruiting
This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period.
Gender:
ALL
Ages:
Between 29 days and 17 years
Trial Updated:
06/11/2025
Locations: Loma Linda University Health System ( Site 0008), Loma Linda, California +92 locations
Conditions: Heart Failure, Left Ventricular Systolic Dysfunction
Register for Updates
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
NCT05462106
Recruiting
The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.
Gender:
ALL
Ages:
Between 35 years and 85 years
Trial Updated:
06/11/2025
Locations: Barrow Neurological Institute, Phoenix, Arizona +18 locations
Conditions: Alzheimer's Disease, Prodromal Alzheimer's Disease, Amyloid Plaque, Beta-Amyloid, Alzheimer's Disease in Down Syndrome
Register for Updates